GMED vs. NBIX
GMED (Globus Medical, Inc.) and NBIX (Neurocrine Biosciences, Inc.) are both stocks. Both are in the Healthcare sector — GMED in Medical Devices, NBIX in Drug Manufacturers - Specialty & Generic. Over the past 10 years, GMED returned 12.07%/yr vs 13.85%/yr for NBIX. At a 0.29 correlation, their price movements are largely independent.
Performance
GMED vs. NBIX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GMED achieves a -10.54% return, which is significantly lower than NBIX's 24.87% return. Over the past 10 years, GMED has underperformed NBIX with an annualized return of 12.07%, while NBIX has yielded a comparatively higher 13.85% annualized return.
GMED
- 1D
- 1.92%
- 1M
- -2.99%
- 6M
- -17.32%
- YTD
- -10.54%
- 1Y
- 36.75%
- 3Y*
- 8.91%
- 5Y*
- -0.63%
- 10Y*
- 12.07%
NBIX
- 1D
- -1.91%
- 1M
- 8.85%
- 6M
- 30.43%
- YTD
- 24.87%
- 1Y
- 32.71%
- 3Y*
- 21.73%
- 5Y*
- 12.33%
- 10Y*
- 13.85%
GMED vs. NBIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GMED Globus Medical, Inc. | -10.54% | 5.56% | 55.21% | -28.25% | 2.87% | 10.70% | 10.77% | 36.04% | 5.30% | 65.66% |
NBIX Neurocrine Biosciences, Inc. | 24.87% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
Correlation
The correlation between GMED and NBIX is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Aug 3, 2012 | 0.29 |
The correlation between GMED and NBIX shifts across timeframes, from 0.19 (1 year) to 0.29 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
GMED:
$10.53B
NBIX:
$17.81B
GMED:
$4.28
NBIX:
$6.50
GMED:
18.23
NBIX:
27.23
GMED:
0.19
NBIX:
0.54
GMED:
3.45
NBIX:
5.87
GMED:
2.28
NBIX:
5.37
GMED:
$3.10B
NBIX:
$3.10B
GMED:
$1.58B
NBIX:
$3.05B
GMED:
$803.34M
NBIX:
$881.20M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GMED vs. NBIX — Risk / Return Rank
GMED
NBIX
GMED vs. NBIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Globus Medical, Inc. (GMED) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GMED | NBIX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.28 | ||
| Sortino ratioReturn per unit of downside risk | +0.26 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 1.20 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 1.60 | 1.50 | +0.09 |
| Martin ratioReturn relative to average drawdown | 3.87 | 3.29 | +0.57 |
Loading charts...
Drawdowns
GMED vs. NBIX - Drawdown Comparison
The maximum GMED drawdown since its inception was -47.91%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for GMED and NBIX.
Loading charts...
Drawdown Indicators
| GMED | NBIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -47.91% | -97.21% | +49.30% |
Max Drawdown (1Y)Largest decline over 1 year | -22.10% | -20.90% | -1.20% |
Max Drawdown (3Y)Largest decline over 3 years | -44.40% | -42.89% | -1.51% |
Max Drawdown (5Y)Largest decline over 5 years | -47.91% | -42.89% | -5.02% |
Max Drawdown (10Y)Largest decline over 10 years | -47.91% | -46.39% | -1.52% |
Current DrawdownCurrent decline from peak | -19.32% | -1.91% | -17.41% |
Average DrawdownAverage peak-to-trough decline | -15.33% | -43.74% | +28.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.13% | 9.52% | -0.39% |
Volatility
GMED vs. NBIX - Volatility Comparison
Globus Medical, Inc. (GMED) has a higher volatility of 13.69% compared to Neurocrine Biosciences, Inc. (NBIX) at 8.08%. This indicates that GMED's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GMED | NBIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.69% | 8.08% | +5.61% |
Volatility (6M)Calculated over the trailing 6-month period | 25.33% | 23.42% | +1.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.46% | 31.73% | +17.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.27% | 32.83% | +5.44% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.68% | 39.03% | -3.35% |
Dividends
GMED vs. NBIX - Dividend Comparison
Neither GMED nor NBIX has paid dividends to shareholders.
Financials
GMED vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between Globus Medical, Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GMED vs. NBIX - Profitability Comparison
GMED - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Globus Medical, Inc. reported a gross profit of 0.00 and revenue of 759.85M. Therefore, the gross margin over that period was 0.0%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
GMED - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Globus Medical, Inc. reported an operating income of 150.39M and revenue of 759.85M, resulting in an operating margin of 19.8%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
GMED - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Globus Medical, Inc. reported a net income of 124.30M and revenue of 759.85M, resulting in a net margin of 16.4%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
Frequently Asked Questions
GMED and NBIX have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GMED has higher volatility (13.69%) compared to NBIX (8.08%). In terms of maximum drawdown, GMED dropped -47.91% vs NBIX's -97.21%.
NBIX currently has the higher Sharpe Ratio (0.99 vs 0.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GMED and NBIX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer